{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:30Z","timestamp":1786980570795,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01658-3","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T02:56:57Z","timestamp":1747018617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial"],"prefix":"10.1007","volume":"25","author":[{"given":"Huacong","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng\u2019e","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"08","key":"1658_CR1","first-page":"617","volume":"41","author":"Thrombosis and Hemostasis Group CSoH","year":"2020","unstructured":"Thrombosis and Hemostasis Group CSoH. Chinese Medical Association. Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020). Chin J Hematol. 2020;41(08):617\u201323.","journal-title":"Chin J Hematol"},{"issue":"3","key":"1658_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.21616","volume":"85","author":"DR Terrell","year":"2010","unstructured":"Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174\u201380. https:\/\/doi.org\/10.1002\/ajh.21616.","journal-title":"Am J Hematol"},{"issue":"9","key":"1658_CR3","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ajh.23262","volume":"87","author":"DR Terrell","year":"2012","unstructured":"Terrell DR, Beebe LA, Neas BR, et al. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012;87(9):848\u201352. https:\/\/doi.org\/10.1002\/ajh.23262.","journal-title":"Am J Hematol"},{"key":"1658_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1196\/annals.1361.118","volume":"1051","author":"T Sapir","year":"2005","unstructured":"Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci. 2005;1051:743\u201378. https:\/\/doi.org\/10.1196\/annals.1361.118.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"1658_CR5","first-page":"328","volume":"5","author":"JG Bullowa","year":"1929","unstructured":"Bullowa JG. The serum treatment and its evaluation in lobar pneumonia. Bull N Y Acad Med. 1929;5(4):328\u201362.","journal-title":"Bull N Y Acad Med"},{"issue":"8232","key":"1658_CR6","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/s0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d\u2019Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228\u201331. https:\/\/doi.org\/10.1016\/s0140-6736(81)92400-4.","journal-title":"Lancet"},{"key":"1658_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6020016","author":"A Zufferey","year":"2017","unstructured":"Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017. https:\/\/doi.org\/10.3390\/jcm6020016.","journal-title":"J Clin Med"},{"issue":"10","key":"1658_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1177\/0961203317696589","volume":"26","author":"A Watad","year":"2017","unstructured":"Watad A, Amital H, Shoenfeld Y. Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions. Lupus. 2017;26(10):1015\u201322. https:\/\/doi.org\/10.1177\/0961203317696589.","journal-title":"Lupus"},{"key":"1658_CR9","doi-asserted-by":"publisher","first-page":"101141","DOI":"10.1016\/j.blre.2023.101141","volume":"63","author":"T Moulinet","year":"2024","unstructured":"Moulinet T, Moussu A, Pierson L, et al. The many facets of immune-mediated thrombocytopenia: principles of immunobiology and immunotherapy. Blood Rev. 2024;63:101141. https:\/\/doi.org\/10.1016\/j.blre.2023.101141.","journal-title":"Blood Rev"},{"issue":"03","key":"1658_CR10","first-page":"204","volume":"40","author":"YR Sun Boyang","year":"2017","unstructured":"Sun Boyang YR. Pathogenesis of immune thrombocytopenic purpura. Int J Blood Transfus Hematol. 2017;40(03):204\u20138.","journal-title":"Int J Blood Transfus Hematol"},{"issue":"1","key":"1658_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5694\/mja2.51284","volume":"216","author":"PY Choi","year":"2022","unstructured":"Choi PY, Merriman E, Bennett A, et al. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. Med J Aust. 2022;216(1):43\u201352. https:\/\/doi.org\/10.5694\/mja2.51284.","journal-title":"Med J Aust"},{"issue":"23","key":"1658_CR12","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966.","journal-title":"Blood Adv"},{"issue":"1","key":"1658_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5045\/br.2022.2022043","volume":"57","author":"YH Park","year":"2022","unstructured":"Park YH, Kim DY, Kim S, et al. Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. Blood Res. 2022;57(1):20\u20138. https:\/\/doi.org\/10.5045\/br.2022.2022043.","journal-title":"Blood Res"},{"issue":"19","key":"1658_CR14","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.3346\/jkms.2018.33.e142","volume":"33","author":"J Hong","year":"2018","unstructured":"Hong J, Bang SM, Mun YC, et al. Efficacy and safety of a new 10% intravenous immunoglobulin product in patients with primary immune thrombocytopenia (ITP). J Korean Med Sci. 2018;33(19):e142. https:\/\/doi.org\/10.3346\/jkms.2018.33.e142.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"1658_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.14740\/jh385w","volume":"7","author":"F Rodeghiero","year":"2018","unstructured":"Rodeghiero F, Woszczyk D, Slama B, et al. Efficacy and Safety of IQYMUNE\u00ae, a ten percent intravenous immunoglobulin in adult patients with chronic. Primary Immune Thrombocytopenia J Hematol. 2018;7(3):87\u201395. https:\/\/doi.org\/10.14740\/jh385w.","journal-title":"Primary Immune Thrombocytopenia J Hematol"},{"issue":"2","key":"1658_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/tme.12943","volume":"33","author":"J Demeter","year":"2023","unstructured":"Demeter J, Hamed A, L\u00e1szl\u00f3 S, et al. Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia. Transfus Med. 2023;33(2):165\u201373. https:\/\/doi.org\/10.1111\/tme.12943.","journal-title":"Transfus Med"},{"issue":"4","key":"1658_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1179\/102453309x439773","volume":"14","author":"T Robak","year":"2009","unstructured":"Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227\u201336. https:\/\/doi.org\/10.1179\/102453309x439773.","journal-title":"Hematology"},{"issue":"1","key":"1658_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/tme.12573","volume":"29","author":"O Arbach","year":"2019","unstructured":"Arbach O, Taumberger AB, Wietek S, et al. Efficacy and safety of a new intravenous immunoglobulin (Panzyga(\u00ae) ) in chronic immune thrombocytopenia. Transfus Med. 2019;29(1):48\u201354. https:\/\/doi.org\/10.1111\/tme.12573.","journal-title":"Transfus Med"},{"issue":"13","key":"1658_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2217\/imt-2017-0071","volume":"9","author":"RL Wasserman","year":"2017","unstructured":"Wasserman RL. Gammaplex(\u00ae) 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura. Immunotherapy. 2017;9(13):1071\u201388. https:\/\/doi.org\/10.2217\/imt-2017-0071.","journal-title":"Immunotherapy"},{"issue":"3","key":"1658_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10875-022-01397-0","volume":"43","author":"G Kriv\u00e1n","year":"2023","unstructured":"Kriv\u00e1n G, Borte M, Soler-Palacin P, et al. BT595, a 10% human normal immunoglobulin, for replacement therapy of primary immunodeficiency disease: results of a subcohort analysis in children. J Clin Immunol. 2023;43(3):557\u201367. https:\/\/doi.org\/10.1007\/s10875-022-01397-0.","journal-title":"J Clin Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01658-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01658-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01658-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:54Z","timestamp":1764917334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01658-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01658-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval for the study was obtained from Peking Union Medical College Hospital of ethics committee (Date 2018; No.2018L03309). All of the patients had consented to research authorization for record review, and the study was approved by the institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. (A copy of the written consent is available for review by the Editor-in-Chief of this journal).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"153"}}